---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-353308"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2026-08-17T12:50:21+00:00"
generated_at: "2026-08-17T12:55:34.785825+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# EyePoint DURAVYU LUGANO trial misses primary endpoint; secondary endpoints strong

## Summary
- Primary endpoint not met in full dataset; ad hoc analysis excluding 4% asymmetric cohort (9/211) showed non-inferiority to aflibercept (p=0.0096).
- 42% reduction in treatment burden vs aflibercept (p<0.0001); 76% supplement-free to Week 32, 54% to Week 56.
- 79% of DURAVYU patients received 0 or 1 supplement up to Week 56; supplement-free BCVA non-inferior (p=0.0035).
- LUCIA topline expected Q4 2026; NDA filing planned 1H 2027; DME trials COMO/CAPRI topline Q4 2027.

## SEC filing metadata
- accession: 0001193125-26-353308
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2026-08-17T12:50:21+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/0001193125-26-353308-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-20260817.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-353308
- JSON: https://secwatch.observer/filing/0001193125-26-353308.json
- Plain text: https://secwatch.observer/filing/0001193125-26-353308.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.